Impact of proactive low-molecular weight heparin therapy on outcomes in COVID-1
| Autor: | A Paudel, A Degirmencioglu, E Ekicibasi, F Atalar, B Pamukcu, Ceyda Kirisoglu, E Eroglu, H K Gumusel, Refik Erdim, N Sariguzel, S Gormez, G Akan, S Dagdelen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Economics and Econometrics
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Low molecular weight heparin law.invention law Internal medicine Materials Chemistry Media Technology Humans Medicine Retrospective Studies Mechanical ventilation Heparin SARS-CoV-2 business.industry Anticoagulants COVID-19 Forestry Retrospective cohort study Heparin Low-Molecular-Weight medicine.disease Thrombosis Intensive care unit Molecular Weight Venous thrombosis Propensity score matching business medicine.drug |
| Zdroj: | Bratislava Medical Journal. 122:582-589 |
| ISSN: | 1336-0345 |
| DOI: | 10.4149/bll_2021_093 |
| Popis: | OBJECTIVES: Low molecular weight heparin (LMWH) may provide beneficial effects on outcomes of COVID-19. We aimed to examine the impact of LMWH treatment on clinical outcomes (duration of hospitalization, admission to intensive care unit, the requirement for mechanical ventilation, and death) of COVID-19 patients with normal D-dimer levels at admission. BACKGROUND: Coronavirus disease-2019 (COVID-19) predisposes patients to arterial and venous thrombosis. METHODS: In this retrospective, multicentre and observational study we analysed the data of 308 confirmed COVID-19 patients with normal D-dimer levels at initial admission. After propensity score matching (PSM) patients were grouped; Group 1; patients who received LMWH with D-dimer ≤0.5 mg/L, Group 2; patients who received LMWH after D-dimer levels exceeded 0.5 mg/L, and Group 3; patients who did not receive LMWH. RESULTS: After PSM, each group comprised 40 patients. The patients in Group1 had the best clinical outcomes compared to the other groups. Group 3 had the worst clinical outcomes (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|